Limb Preservation Platform — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Limb Preservation Platform (LPP) is a niche clinical research organization (CRO) and site specializing in the critical area of diabetic limb salvage and wound healing. It leverages its dedicated facility, certified staff, and key opinion leader principal investigator to attract sponsors developing lower extremity wound care products. Its business model is service-based, generating revenue by conducting clinical trials for external sponsors while offering free, advanced care to a vulnerable patient population. LPP addresses a massive and growing global health crisis driven by diabetes, positioning itself as an expert site in a high-need, complex therapeutic area with significant morbidity and cost.

Diabetic Foot UlcersLower Extremity Wound HealingLimb Preservation

Technology Platform

Integrated clinical research site infrastructure specializing in lower extremity wound trials, featuring on-site diagnostic labs (ECG, ABI, X-ray, Doppler), certified GCP/NIH/IATA staff, and a -80°C freezer, built around key opinion leader clinical expertise.

Opportunities

The massive and growing global epidemic of diabetes, leading to millions of chronic wounds and amputations, creates a sustained and expanding market for advanced therapies.

LPP's deep specialization positions it as a preferred, high-performance site for sponsors, allowing it to command premium service fees and build long-term partnerships in a niche with high barriers to entry.

Risk Factors

Revenue is entirely dependent on a limited pool of pharmaceutical and medical device sponsors, creating client concentration risk.

Patient recruitment for complex wound trials is challenging and delays can damage sponsor relationships.

The company's reputation is heavily reliant on its founding physician, creating key person risk.

Competitive Landscape

LPP competes with other clinical trial sites and generalist CROs for wound care study contracts. Its differentiation lies in its exclusive focus on limb preservation, dedicated facility, and embedded KOL. It faces competition from academic medical centers with wound care centers and large, global CROs that may offer broader geographic reach but less specialized expertise.

More companies in Regenerative Medicine →More companies in United States →